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ABSTRACT 
Antimicrobial peptides (AMPs) constitute front-line components of innate immunity in 
multicellular organisms. AMPs are able to kill a wide range of pathogens and exhibit 
additional important functions such as chemotaxis, angiogenesis and wound healing. 
These peptides are constitutively expressed in immune and/or epithelial cells. However, 
their expression can also be induced or suppressed by different stimuli in a cell and 
tissue specific manner. In this thesis, the functional relevance of cathelicidins and 
defensins, two major families of AMPs in mammals, was studied in the context of 
enteric infectious diseases. Induction of these AMPs was explored in Shigella infection. 
The effect of antibiotics on the expression of AMPs in colonic epithelial cells was also 
investigated and the implication of this effect on Clostridium difficile associated 
diarrhea (CDAD) was assessed. 
In a rabbit model of shigellosis, cathelicidin CAP-18 was downregulated in the large 
intestinal epithelia. Oral treatment with sodium butyrate (NaB) counteracted this 
downregulation and led to the conversion of the proform of CAP-18 into its active form 
in the stool (paper I). These findings correlated with reduced Shigella load in the 
intestinal lumen and clinical as well as histopathological recovery. Association between 
CAP-18 induction and reduction of bacterial load was supported by partial blocking of 
the antimicrobial activity in stool extract of a butyrate treated rabbit with CAP-18 
specific antibody along with in vitro shigellacidal activity of CAP-18 peptide. In 
patients with shigellosis, administration of NaB enema as adjunct to antibiotic therapy 
led to an early improvement of rectal histopathology along with early reduction of 
inflammatory cells and proinflammatory cytokines in the stool compared to placebo 
treated patients (paper II). NaB treatment also resulted in enhanced expression of the 
human cathelicidin LL-37 in the rectal epithelia and sustained secretion of LL-37 in the 
stool. Since all patients were treated with antibiotics, attenuation of Shigella load in 
stool and clinical symptoms occurred simultaneously in both group of patients. 
Sodium-4-phenyl-butyrate (PB), an analogue of butyrate, was demonstrated to exhibit a 
similar therapeutic efficiency as NaB in the rabbit model of shigellosis (paper III). 
Downregulation of CAP-18 expression was also observed in the epithelia of lung and 
trachea. This suppression could render the respiratory tract susceptible to secondary 
infections during shigellosis. After oral treatment with PB or NaB, CAP-18 reappeared 
in the lung epithelia, which might strengthen the immunity of the respiratory tract 
against opportunistic respiratory pathogens. 
Ciprofloxacin and clindamycin were found to suppress butyrate-induced expression of 
LL-37 in the colonic epithelial cell line, HT-29 (paper IV). In vivo inhibitory effect of 
ciprofloxacin was observed on CAP-18 expression in the rectal epithelia of Shigella- 
infected rabbits treated with NaB as well as of healthy rabbits. Induction of genes 
encoding HBD-3 and additional AMPs by NaB were also inhibited by ciprofloxacin. In 
vitro antibacterial activity of LL-37 against ciprofloxacin-resistant C. difficile indicates 
that the reduction of AMPs after antibiotic treatment may allow the overgrowth of C. 
difficile in the gut. 
In conclusion, induction of AMPs is a promising therapeutic strategy against 
shigellosis. Suppression of AMP expression by antibiotics may contribute to CDAD, 
which is classically known to occur through disruption of the intestinal microbiota after 
antibiotic treatment. 
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1 BACKGROUND 
 
1.1 SHIGELLOSIS 
Shigellosis, or bacillary dysentery, is caused by the infection of the large intestinal tract 
by bacteria of the genus Shigella. Shigella is principally a human pathogen, which is 
transmitted via fecal/oral route. The bacteria enter into the body through the ingestion 
of contaminated water or food. The disease is very infectious as 10-100 bacteria are 
sufficient to cause infection. After 12-96 hours of bacterial encounter, the disease 
symptoms are manifested, which range from mild watery diarrhea to severe 
inflammatory colitis. Frequent passage of scanty loose stools containing mucus and/or 
blood is the classical manifestation of shigellosis. Patients with severe shigellosis 
experience fever, abdominal cramp and tenesmus. Mild shigellosis is self-limiting and 
typically lasts for 4-7 days but appropriate medication is required for severe cases. 
Some infected persons may remain as asymptomatic carrier. 
Shigellosis is regarded as one of the major public health burden, 
especially in resource-poor countries. Although, case fatality rate has decreased 
significantly over the last decade, the incidence rate of endemic shigellosis still remains 
very high, which is estimated to be about 125 million cases every year in Asia [1]. 
Children below 5 years of age are more susceptible to fatal shigellosis. The childhood 
death in shigellosis due to colitis is often aided by malnutrition, septicemia and 
secondary respiratory complications such as pneumonia [2-4]. Malnutrition and 
persistent diarrhea are two major long-term consequences of shigellosis. Loss of serum 
proteins during shigellosis [5], results in linear growth stunting in young children who 
do not have access to adequate dietary protein [6]. Moreover, infection with Shigella is 
a risk factor for post-infectious complications, such as reactive arthritis [7] and post-
infectious irritable bowel syndrome (PI-IBS) [8]. 
Shigella is a member of the tribe Escherichia in the family 
Enterobacteriaceae. It is a gram negative, uncapsulated, nonsporulating, nonmotile, 
facultative anaerobic bacillus. Shigella is divided into serogroups and subdivided into 
serotypes based on antigenic difference in the O-specific polysaccharide (O-SP) of 
lipopolysaccharide (LPS) present in the outer membrane. There are 4 species of 
Shigella: S. dysenteriae (group A, 17 serotypes), S. flexneri (group B, 14 serotypes), S. 
boydii (group C, 20 serotypes) and S. sonnei (1 serotype). Three strains are mainly 
responsible for the occurrence of shigellosis: S. dysenteriae type 1, S. flexneri 2a and S. 
sonnei. The first two strains are encountered in developing countries and generally 
cause severe dysentery. S. sonnei is found to cause mild diarrheal illness, mostly in 
industrialized countries. S. dysenteriae type 1 is the only strain found in epidemic and 
also pandemic shigellosis. 
 
1.1.1 Pathogenesis 
Shigella pathogenesis is a multistep process, involving invasion and colonization of 
large intestinal epithelial cells (iEC) and subsequent destruction of the mucosa through 
excessive inflammation (Figure 1).  Shigellae are very inefficient in invading iEC 
through the apical route [9]. Instead, the bacteria enter into the microfold (M) cells of 
the Peyer’s patches and are translocated to the underlying subepithelial pocket [10, 11]. 
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Figure 1: Schematic representation of Shigella pathogenesis. (1) Shigellae cross the intestinal 
epithelial cell (iEC) barrier by transcytosis through M cells and encounter resident macrophages. (2) 
Bacteria are released in the submucosa by inducing death of macrophages. (3) IL-1β is released from the 
dying macrophages, recruiting PMNs to the infection site. (4) Recruited PMNs disrupt iEC tight 
junctions, facilitating paracellular entry of the bacteria. (5) Shigellae invade iEC from basolateral site. (6) 
Bacteria spread to adjacent cells. (7) Infected iEC produce IL-8, forming a positive feedback loop to 
exacerbate inflammation. (8) IL-18, released from dying macrophages, stimulates NK cells to produce 
IFN-γ, leading to protective immune responses. Adopted from reference [12] with minor modifications. 
 
Within the pocket, Shigellae are engulfed by resident macrophages, multiply in 
cytoplasm and disseminate into submucosa by inducing cell death [10, 11, 13, 14]. The 
bacteria also induce release of mature interleukin-1β (IL-1β) and interleukin-18 (IL-18) 
from the dying macrophages, triggering an early inflammation [15-17]. The resulting 
infiltration of polymorphonuclear neutrophils (PMNs) to the infection site breaks the 
epithelial barrier integrity and thus allows more luminal bacteria to accumulate in the 
submucosa without the help of M cells [10]. Shigellae then invade iEC from the 
basolateral site by inducing macropinocytosis and escape into the cytoplasm by 
rapturing vacuole membrane and replicate therein [9, 18]. Utilizing actin-based 
motility, the bacteria move intracellularly and pass to adjacent iEC, leading to their 
spread throughout the tissue [18]. Large array of proinflammatory cytokines and 
chemokines including IL-8 is induced and secreted from the infected iEC, which 
disseminate the inflammation [18-20]. The spread of inflammation is characterized by 
massive influx of PMNs, additional immune cells and accumulation of 
proinflammatory cytokines and other innate mediators [21-26]. Shigella infection 
eventually leads to death of host cells by apoptosis and/or necrosis [22, 27]. The 
consequence of the overall events is huge mucosal damage as evident by epithelial 
erosion, mucosal abscesses and hemorrhages in acute shigellosis [10, 22, 28]. 
Inflammatory response may also persist for a long time after the recovery from clinical 
symptoms, giving rise to chronic illness [23, 25]. 
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1.1.2 Immune responses and immune evasion 
Shigellae encounter several host defense mechanisms on the way to cause infection. 
Virulent Shigellae are highly adaptable to overcome these defenses. The bacteria are 
highly tolerant to the acidic environment [29], hence easily pass through the stomach 
into the intestine. As mentioned in the previous section, Shigellae breach the physical 
barrier of intestinal epithelial lining by exploiting M cells and resident macrophages in 
the subepithelial dome of the lymphoid follicles. The bacteria can also overcome the 
chemical barrier of the epithelia by inhibiting the production of effector molecules such 
as antimicrobial peptides or proteins [30, 31]. By colonizing iEC, Shigellae avoid 
extracellular components of the host immune system such as antibodies or complement 
factors. Self-renewal of intestinal epithelium in every 4-5 days [13] provides a 
functional barrier against bacterial colonization through shedding of infected cells. 
Shigellae can control this rapid turnover of epithelial cells by reducing the cell cycle 
progression of stem cells and by hindering exfoliation of infected iEC [13]. Cytosolic 
pathogens encounter another host defense mechanism called autophagy. 
Autophagosome degrades own components of the cell via lysosomal fusion as part of 
cellular homeostasis, but can also target and destroy intracellular pathogens and/or 
infected cells [32]. Shigella invasion triggers autophagy but the bacteria evade 
autophagic recognition [33]. Although, migrated PMNs initially facilitate translocation 
of Shigellae to the submucosa, the bacteria are eventually killed by the PMNs [21]. In 
addition to intracellular killing, PMNs form neutron extracellular traps (NETs). NETs 
are composed of chromatin fibers, filled with antimicrobial peptides and other granule 
proteins that entrap extracellular Shigellae [34]. This leads to degradation of bacterial 
virulence-associated proteins and subsequent killing of the bacteria. Besides NETs, 
secreted innate immune effectors and inflammatory mediators from immune cells may 
also contribute to Shigellae clearance [24]. However, Shigellae execute various 
strategies to reduce excessive inflammation for their survival. The bacteria induce death 
of the immune cells [22, 27], counterbalance pro-inflammatory responses [35] as well 
as induce the production of antinflammatory mediators [23]. Gamma interferon (IFN-γ) 
is a critical cytokine for immunity against viral and intracellular bacterial pathogens 
[36]. Natural killer (NK) cell-derived IFN-γ was shown to resist pulmonary Shigella 
infection in a mice model through induction of intracellular killing by macrophages 
[37]. Interestingly, IL-18, released from the dying macrophages during early Shigella 
infection promotes IFN-γ production from NK cells (Figure 1) [12]. Upregulation of 
IFN-γ production and enhanced expression of IFN-γ receptors during the recovery 
phase of shigellosis suggests the importance of IFN-γ in controlling Shigella infection 
in humans [38]. However, decreased expression of IFN-γ receptors, reduced secretion 
and extracellular deposition as well as systemic downregulation of IFN-γ at the acute 
stage of shigellosis indicate another immune escape strategy of Shigella during early 
stage of the infection [38-40]. 
Following infection, both systemic and mucosal humoral immune responses 
are augmented against Shigella antigens such as lipopolysaccharide (LPS) and invasion 
plasmid-coded antigens (Ipa) [41, 42]. Mucosal IgA antibodies to Ipa are associated 
with protection from the disease [43]. Induced mucosal and serum antibodies, specific 
for LPS protect re-infection by the same Shigella serotype [44, 45]. We have 
demonstrated that humoral responses in infected children are reduced and delayed 
compared to adults in an endemic setting [42]. In healthy endemic population, the 
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levels of serum antibodies to LPS and Ipa increase with age [42, 46]. Moreover, serum 
antibody levels to both antigens in naïve population from non-endemic areas are 
significantly low compared to that with endemic population [42, 46]. These findings 
indicate that several episodes of infection are needed for building humoral protective 
immunity and explain why children are more susceptible to Shigella infection. Cell 
mediated adaptive immune responses in shigellosis have not been well characterized so 
far. T cells are infiltrated and activated in the intestinal mucosa during shigellosis [26, 
47], but their responses to Shigella remains poorly understood. It has recently been 
demonstrated that antigen-specific CD8+ T cells are not primed during Shigella 
infection [48]. CD4+ T cells are invaded by Shigellae and do not respond to chemokine-
induced migration [49]. However, in a murine pulmonary infection model, Shigella-
primed Th17 cells was shown to exhibit protective immune response against the same 
strain up to 12 months after priming [50]. 
 
1.1.3 Virulent factors responsible for pathogenesis and immune 
evasion 
Secretion of several diverse effectors via type III secretion apparatus (TTSA) is the 
principle virulent determinants of Shigella. The majority of the effectors and TTSA are 
encoded by a large (~ 200 kb) virulence plasmid [12]. A conserved 31 kb entry region 
of the plasmid is considered as the main Shigella pathogenicity island (PAI). This 
region encodes (i) the components of the TTSA (mxi-spa locus), (ii) substrates of 
TTSA (the translocators IpaB and IpaC and the effectors IpaD, IpgB1, IpgD and IcsB), 
(iii) chaperons (IpgA, IpgC, IpgE and Spa15) to which the substrates remain bound 
inside bacterial cytoplasm before being secreted and (iv) transcriptional activators 
(VirB and MxiE) [51]. Other substrates of TTSA, i.e. VirA, OspB-G, and IpaH are 
encoded outside the PAI region. Five other virulent proteins encoded by plasmid are 
IcsA (VirG), IcsP, VirK, MsbB2 and SepA [51]. Recognition of pathogen-associated 
molecular patterns (PAMPs) by pattern recognition receptors (PRRs) of the host is also 
crucial for the pathogenesis and immune responses elicited by Shigella [13, 35]. 
IpB mediates apoptosis of macrophages by activating caspase-1[52]. Sensing 
of bacterial components by nucleotide-binding oligomerisation domain (NOD)-like 
receptors (NLRs) also leads to pyroptosis of macrophages [35]. Activated caspase-1 
hydrolyzes pro-IL-1β and pro-IL-18 and thus allows the release of mature IL-1β and 
IL-18 [15]. Delivery of a subset of effectors including IpaA, IpaB, IpaC, IpgB1, IpgB2, 
IpgD and VirA promotes basolateral entry of bacteria into the iEC cells through 
formation of membrane-ruffles [53]. VirG and VirA mediate intra- and inter-cellular 
movement of the bacteria through actin polymerization and degradation of 
microtubules [53]. IcsB, by binding to VirG prevent recognition of VirG by autophagy 
related protein 5 (Atg5) and hence evade autophagy [33]. The binding of peptidoglycan 
fragments of the bacteria to NLRs triggers the production of proinflammatory cytokines 
through the activation of nuclear factor κB (NF- κB) [35]. IpaH, OspG, OspF and OspZ 
downregulate host inflammatory responses by inhibiting NF-κB activation [35]. The 
secretion of IpaB slows down the cell cycle progression of epithelial progenitor cells 
[13]. iEC exfoliation/ detachment is inhibited by OspE [13]. IpgD impairs the 
chemokine-induced migration of CD4+ T cells [49]. 
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1.1.4 Treatment 
WHO recommends that all episodes of bloody diarrhea should be treated with 
antibiotics and the choice of antibiotics should be based on local or at least on regional 
susceptibility data [54]. Nalidixic acid, ampicillin, chloramphenicol, co-trimoxazole 
and tetracycline, which were used in the past, are no longer recommended, because of 
widespread resistance of Shigella spp. to these antibiotics. In the absence of local or 
regional data, WHO recommends ciprofloxacin as the first choice of antibiotic for 
patients with bloody diarrhea, irrespective of their age. Fluoroquinolones other than 
ciprofloxacin, pivmecillinam and ceftriaxone are recommended as second line 
antimicrobials for all age group, while azithromycin is recommended only for adults. 
However, resistant Shigella strains to ceftriaxone and fluoroquinolones including 
ciprofloxacin have been emerging in recent years [55, 56]. The usage of rehydration 
therapy for all age groups and zinc supplementation for children up to 5 years of age 
are recommended for diarrheal diseases including shigellosis. 
 
1.1.5 Preventive measures and vaccines 
Provision of clean water, proper nutrition and good hygiene practice are the critical 
preventive measures against shigellosis as well as other infectious diarrheal diseases.  
For several decades, attempts have been made to develop Shigella vaccine but a 
safe and protective vaccine is still elusive. Shigella vaccine candidates are broadly 
categorized as killed whole bacterium, live attenuated and subunit vaccines. A number 
of live attenuated vaccine candidates have been developed against S. flexneri [57]. 
Among these candidates, SC602, at 104 cfu dose, was shown to be safe and to induce 
strong immune responses in US volunteers [58]. It also conferred protection to a 
subgroup of volunteers, who were challenged with parental strain two months later 
[58]. However, a recent double-blind, randomized clinical trial in an endemic setting in 
Bangladesh, has failed to show the immunogenicity of SC602 in adults and school 
children [59]. CVD 1207 and CVD 1208 also have shown promise in phase I clinical 
trials in USA [57]. SC599, a S. dysenteriae 1 vaccine candidate, have undergone 
successful phase I and II trials in European populations [60, 61]. A S. sonnei vaccine 
candidate, WRSS1 has been shown to be safe and immunogenic in US and Israeli 
volunteers [57].  
Approaches for subunit vaccine are based on the use of protective antigen(s) 
such as LPS and Ipa proteins. S sonnei and/or S flexneri conjugate vaccines based on O-
SP have been demonstrated to be safe and to stimulate LPS specific antibodies in 
adults, 4-7 years old children and in 1-4 years old children [62]. Vaccine based on 
Shigella invasion complex (Invaplex, a complex of LPS, IpaB, IpaC and IpaD), have 
been shown to exert minimum side effects and give rise to protective immune response 
in phase I clinical trials [62]. 
 
1.2 ANTIBIOTIC-ASSOCIATED DIARRHEA (AAD) 
Antibiotics are the mainstay of therapy against bacterial infections. Besides, killing or 
inhibiting bacterial pathogens, antibiotics may upset the normal gut flora, allowing 
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opportunistic pathogens such as Clostridium difficile, Clostridium perfringens, 
Staphylococcus aureus and Klebsiella oxytoca to colonize the gut mucosa [63]. 
Infection by these pathogens may lead to mucosal deterioration and diarrhea. 
Disruption of the normal flora may also account for reduced microbial metabolism of 
carbohydrates and primary bile acids, leading to osmotic or secretory diarrhea. 
Moreover, antibiotics may directly alter the motility of the gut, causing diarrhea [63]. 
These diarrheal events due to antibiotic usage are collectively termed antibiotic- 
associated diarrhea (AAD). AAD constitutes 5-25% of all diarrheal incidences [63]. 
 
1.2.1 Clostridium difficile associated diarrhea (CDAD) 
CDAD is on the top of the list among all AAD, accounting for 15-25% of all cases 
[64]. Clindamycin, ampicillin, amoxicillin, cephalosporin and fluroquinolones are the 
major antibiotics implicated in CDAD. Vancomycin and metronidazole, commonly 
used to treat CDAD, can also be responsible for subsequent CDAD.  Long duration of 
antibiotic treatment and use of multiple antibiotics increase the risk of Clostridium 
difficile infection (CDI) [64]. Impairment of immune functions due to age, malnutrition, 
shock, HIV infection, severe underlying diseases, and usage of immunosuppressive and 
chemotherapeutic drugs is also a major predisposing factor for CDAD. Some 
chemotherapeutic drugs also affect the normal flora [64]. Inhibition of gastric acid 
secretion by the use of proton pump inhibitors (PPI) or H2 blockers contribute to CDI, 
probably due to increased survival of spores at elevated pH [64]. Inflammatory bowel 
disease (IBD) and bowel surgery are other important risk factors for CDAD [64]. 
Patients staying in health care facility for prolonged period are in risk of 
acquiring CDI, where pathogens can easily be transmitted and patients are often treated 
with antibiotics. Elderly people (>65 years) are more susceptible to CDAD because of 
impaired immunity, receiving antibiotics more often and possibility of being 
hospitalized for longer periods [64]. 
 
1.2.1.1 Transmission and pathogenesis 
C. difficile is a gram-positive, obligate anaerobic, spore-forming bacillus. Spores can 
survive in the harsh environment for longer period and can withstand common 
sterilization methods including high temperature, ultraviolet light and chemicals. 
Spores are transmitted via the fecal-oral route, through the hands of patients, health care 
workers or visitors. In addition, contaminated commodes, bathtubs and medical 
equipment are the potential transmitters of the spores. 
Ingested C. difficile spores germinate in the large intestine and vegetative 
forms multiply. Vegetative bacteria penetrate the mucus layer with the help of flagella 
and proteases and adhere to the iEC through multiple adhesins [65]. Adherent bacteria 
then produce toxins, which are the main virulent determinant of C. difficile. Virulent 
strains generally produce two exotoxins i.e. toxin A (TcdA) and toxin B (TcdB). Both 
toxins are cytotoxic, disrupting the actin cytoskeleton by uridine diphosphate/glucose 
dependent glycosylation of Rho GTPase family. [66]. This cytotoxic effect loosens the 
iEC tight junctions, leading to increased epithelial permiability and fluid accumulation. 
Toxins also induce iEC, mast cells and macrophages to release inflammatory mediators 
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and activate sensory nerves to release neuropeptides [66, 67]. These mediators 
chemoattract PMNs and other inflammatory cells and thereby induce strong 
inflammatory responses and exacerbate fluid accumulation [66]. Although both toxins 
cause disease, toxin B is more potent than toxin A in damaging epithelial barrier [68] 
and is essential for full expression of CDI in hamster model of CDAD [69]. 
Consistently, TcdA-TcdB+ strains were identified from patients with severe CDAD 
[70]. Some strains also produce a binary toxin (CDT), consisting of both binding and 
enzymatic components [71]. Through ADP ribosyl transferase activity, binary toxin can 
disorganize cytoskeleton and hence may enhance the severity of CDAD [71]. 
The CDI cycle including transmission, pathogenesis and risk factors is 
depicted in figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Clostridium difficile infection cycle. iEC: intestinal epithelial cells; CDAD: C. difficile 
associated diarrhea 
 
1.2.1.2 Clinical spectrum 
The clinical spectrum of C. difficile infection, in ascending order of severity, includes 
asymptomatic carriage, diarrhea, colitis without pseudomembrane formation 
(nonspecific colitis), pseudomembranous colitis (PMC) and fulminant colitis (FC) [72]. 
Diarrhea is sometimes accompanied by lower abdominal cramps and is generally 
resolved after stopping antibiotic treatment. Nonspecific colitis is the most common 
clinical feature of CDAD, characterized by malaise, abdominal pain, nausea, anorexia 
and watery diarrhea. PMC is manifested by abdominal cramps and profuse watery, 
green, foul smelling or bloody diarrhea with increased leukocytosis and enhanced 
number of fecal leukocytes. Multiple yellow-white friable plaques attached to 
underlying mucosa are observed endoscopically.  Fibrinous exudate containing 
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lymphocytes, epithelial cells and mucin is the histopathological feature of PMC. FC is 
the most severe form of colitis often demonstrated by fever, severe lower quadrant or 
diffuse abdominal pain accompanied by distention, electrolyte disturbances, lactic 
acidosis, marked leukocytosis and hypoalbuminemia. FC often leads to bowel 
perforation, toxic megacolon and subsequent death.  
Recurrent CDAD, reported in ∼20% of patients, is another major 
complication of C. difficile infection [73]. Within a few days or weeks of stopping C. 
difficile treatment, symptoms of CDAD may re-appear.  Repeated occurrence might be 
a result of persistence of imbalanced fecal flora due to repeated antibiotic treatment or 
of impaired immune responses. 
 
1.2.1.3 Epidemiology 
In recent years the incidence and severity of CDAD have dramatically increased [74]. 
Moreover, the infection is spreading to population previously considered at low risk 
including infants and children, healthy persons living in community and peripartum 
women [74]. The changing epidemiology of CDAD is largely due to the emergence of 
a new hypervirulent strain, accounting for several outbreaks in North America and 
Europe from the beginning of this century [65, 74]. This strain is designated as the 
North American pulse-field gel electrophoresis type 1 (NAP1), restriction endonuclease 
type BI, polymerase chain reaction (PCR) ribotype 027 (NAP1/BI/027). Epidemic 
hypervirulent 027 strain is resistant to fluoroquinolones, erythromycin and clindanycin. 
This toxinotype III strain produces high amount of toxin A and B and also contains 
binary toxin. 
 
1.2.1.4 Preventive measures 
According to the most recent (2010) clinical practice guidelines for CDI in adults by 
the Society for Healthcare Epidemiology of America (SHEA) and the Infectious 
Diseases Society of America (IDSA), following preventive measures should be taken 
[75]. (1) To prevent the transmission of the pathogen, each patient with CDAD should 
be accommodated in a private room or at least be provided with a dedicated commode. 
Health care workers and visitors should use gloves and gowns when entering the room 
of a patient and must wash their hands with soap and water afterwards. Environmental 
decontamination should be routinely carried out with chlorine-containing or other 
sporicidal agents. (2) To minimize the risk of CDI, the frequency and duration of 
antibiotic therapy and number of antibiotics should be minimized.  
 
1.2.1.5 Treatment 
First step in treating patients with CDAD is to withdraw antibiotics being given for 
other purposes or at least changing antibiotic regimens. This strategy very often 
provides early resolution of diarrheal symptoms and even some cases of established 
PMC [64]. If this strategy does not work, patients should be treated with specific 
antibiotic therapy. According to the Clinical practice guidelines for CDI in adults by 
SHEA and IDSA, oral metronidazole is the drug of choice for initial mild or moderate 
episodes and for first recurrence [75]. This drug is not recommended for longer therapy 
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because of neurotoxicity. For initial severe episode or for second recurrence, oral 
vancomycin is recommended. Severe, complicated CDI is recommended to be treated 
with oral vancomycin with or without intravenous metronidazole [75]. Fidaxomicin, a 
macrolid antibiotic has been approved by FDA very recently for treatment of CDAD in 
adults [74]. Alternative approaches such as use of probiotics and immune therapy have 
been and is currently being evaluated. However, the usage of probiotics is not 
recommended by the SHEA and IDSA guidelines because of insufficient data and the 
risk of bloodstream infection [75]. In a phase II randomized clinical trial, co-
administration of antibodies to toxin A and toxin B as adjunctive therapy to classical 
antibiotics was shown to decrease the recurrence rate of CDI [76]. Subtotal colectomy 
is recommended for severely sick patients, when lactate level rises to 5mmol/L and 
blood leukocyte counts increases to 50000cells/µL[75]. 
 
1.3 ANTIMICROBIAL PEPTIDES 
Antimicrobial peptides (AMPs), as the name implies, are peptides having antimicrobial 
activity. These peptides are able to kill a wide range of microorganisms including 
bacteria, viruses and fungi. AMPs are present in almost all living organisms including 
vertebrates, invertebrates, plants, insects and even in microorganisms, indicating that 
these peptides are evolutionary conserved [77]. In multicellular organisms, AMPs are 
important effector molecules of innate immunity. In 1981, Hans G Boman and 
coworkers discovered the first AMPs from the silk moth, Hyalophora cecropia [78]. 
They isolated and characterized two AMPs from the hemolymph of the moth and 
showed efficient killing capacity of these peptides against bacteria. They named the 
peptides cecropins based on the origin of the species. Within a few years, the 
mammalian AMPs were discovered in rabbit macrophages and human PMNs [79, 80]. 
Isolation and characterization of magainins in the skin of African clawed frog Xenopus 
laevis by Michael Zasloff is another revolutionary discovery in this research field [81]. 
The research field on AMPs then flourished and many AMPs from different sources 
have been and are currently being characterized. At present, more than 1200 AMPs 
have been characterized or predicted from gene sequences [82]. Several mimics of 
AMPs have also been developed [83]. 
AMPs are highly variable in their primary, secondary and tertiary structure, i.e. 
α-helical, β- sheet, extended helices rich in certain amino acids and loop structures [77]. 
However, there are some common features in their structures: these peptides are <100 
amino acid (aa) residues long, cationic and amphipathic (one hydrophobic side and one 
ionic side). Positively charged AMPs bind to negatively charged components of 
microbial membrane such as phospholipid, LPS, lipoteichoic acid and peptidoglycan 
via electrostatic interaction [84]. The amphipathic nature of the peptides allows them to 
be incorporated into lipid bilayer of the membrane. This interaction destroys the 
membrane integrity and subsequently the microbes are lysed. Several mechanistic 
models have been developed to delineate the bacterial membrane disruption by AMPs 
[84]. In barrel-stave pore model and in toroidal pore model AMPs (generally α-helical 
peptides) form transmembrane pores in the bacterial membrane. In the carpet model, 
peptides accumulate on the bacterial surface and form a carpet-like structure that lie in 
parallel with the membrane. AMPs then disrupt the membrane in a detergent-like 
manner. In addition, some peptides target different intracellular components or 
 18 
 
processes to kill microorganisms [84]. After being translocated into cytoplasm these 
peptides affect the cytoplasmic membrane septum formation, inhibit synthesis of cell 
wall/nucleic acids/proteins or hinder the enzymatic activities of the microbes. AMPs 
can also be cytotoxic to eukaryotic cells, but at much higher concentration than the 
bactericidal concentration [85]. The presence of neutral zwitterions and cholesterol in 
eukaryotic membrane results in a week interaction with AMPs [77]. 
 Besides antimicrobial activity, several AMPs participate in immunomodulatory 
activities such as chemotaxis, activation and alteration of cytokine/chemokine 
responses of both innate and adaptive immune cells [86, 87]. AMPs thus form a bridge 
between innate and adaptive immune system. Additional functions attributed to these 
peptides are neutralization of LPS [88, 89], regulation of the normal flora [90], wound 
repair and maintenance of epithelial barrier integrity [91-95]. Because, of their 
multifaceted activities in host defense, AMPs are often termed as host defense peptides 
(HDPs) and for their immunomodulatory properties, they are also designated as 
alarmins. 
 
1.3.1 Cathelicidin 
Cathelicidin is one of the main families of AMPs in mammals [87], found also 
in fish [96], birds [97] and amphibians [98]. This diverse group of AMPs is gene-
encoded and produced as preproprotein (128-143 amino acid residues), consisting of a 
conserved cathelin domain (99-114 residues), connected to an N-terminal signal 
peptide (29-30 residues) and a highly variable C-terminal domain (12-100 residues) 
[99]. Upon release of the signal peptide, the proprotein (precursor protein) is stored 
inside the cells. Based on the conservation of the cathelin domain, Zanetti et al. coined 
the term cathelicidins for this group of precursor proteins [99]. When the proprotein is 
released from activated cells, the C-terminal domain is cleaved off from the cathelin 
domain to generate active mature peptide [87]. The free cathelin protein inhibits 
cysteine protease activity and can also elicit antimicrobial activity [100]. Active 
cathelicidin peptides vary considerably in structure. They can be α-helical (such as LL-
37, rabbit CAP-18), can form β-hairpins (such as pig protegrin 1-5) or can have 
extended helices due to abundance of certain amino acid residues (such as porcine PR-
39) [87].  
 
 
 
 
 
 
 
Figure 3: Schematic representation of cathelicidin genes and proteins. The genes consist of 4 exons. 
The first three exons encode the signal peptide and cathelin, while the fourth exon encodes the mature 
active peptide and the processing site.  
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The genes encoding cathelicidins consist of four exons. The first three exons 
encode the signal peptide and the cathelin domain and the fourth exon encodes the 
processing site and the antimicrobial peptide domain (Figure 3). The number of genes 
varies from species to species. For example, human, rabbit, mouse and rat have single 
gene, while cows, pigs and sheep have several genes [87]. 
 
1.3.1.1 LL-37 and its orthologues 
LL-37 is the sole cathelicidin peptide in human. This peptide is 37 residues long and 
contains two leucine residues at the N-terminus and therefore named LL-37. The first 
clones encoding the peptide were obtained through screening of a human bone marrow 
cDNA library and the putative peptide was designated FALL-39 [101]. The FALL-39 
transcript was detected in testis along with bone marrow by Northern blot analysis. In 
the following year, the mature peptide was isolated from degranulated PMNs and 
structural analysis revealed the peptide to be LL-37 [102]. Since then, LL-37 has been 
detected in additional cell types including monocytes, different lymphocytes, mast 
cells, eosinophils, dendritic cells, Langerhans cells and many epithelial cells [103-112]. 
The mammary, salivary and sweat glands have also been shown to express LL-37 [113-
115]. The gene encoding proprotein of LL-37 is designated CAMP (cathelicidin 
antimicrobial peptide) and is located on chromosome 3p21.3 [116]. The proform is a 18 
kDa protein and termed human cationic antimicrobial protein (hCAP)-18 [88]. The 
extracellular cleavage of hCAP-18, generating LL-37 is mediated by proteinase 3 in 
PMNs [117] and kallikrein 5 in skin epithelia [118]. Further processing of LL-37 by 
kallikrein 5 and 7 generates shorter peptides, exhibiting differential antimicrobial 
activity. In seminal plasma, the processing of hCAP-18 by gastricsin results in one 
residue longer peptide (ALL-38) [119].  
The orthologues of LL-37 in rabbit is CAP-18 [89], in mouse is mCRAMP 
[120] and in rat is rCRAMP [121]. LL-37 and all its orthologues are α-helical in 
structure. 
The expression of LL-37 or its orthologues can be constitutive or induced by 
different stimuli. Induced expression of LL-37 is observed in psoriatic lesions [107, 
122] as well as in inflamed and non-inflammed colonic mucosa of patients with 
ulcerative colitis [123]. Induction of LL-37 has also been noted in bacterial and 
parasitic infections such as by Staphylococcus aureus in keratinocytes [124], 
Helicobacter pylori in gastric epithelial cells [111], uropathogenic Escherichia coli in 
epithelial cells of the urinary tract [112] and Entamoeba histolytica in colonic epithelial 
cells [125]. mCRAMP is upregulated by Group A Streptococcus (GAS) in 
keratinocytes [106], by uropthogenic E. coli in the tubular epithelial cells of kidney 
[112] by Neisseria meningitidis in blood brain barrier [126] and by E. histolytica in 
cecal epithelia [125]. The Growth factors, insulin-like growth factor-1 (IGF-1) and 
transforming growth factor-α (TGF-α) also induce the expression of LL-37 in 
keratinocytes [127]. Hypoxia-inducible factor 1, α subunit (HIF-1α) in myeloid cells 
[128] and reactive oxygen species (ROS) in macrophages [129] have been found to 
boost mCRAMP expression. 
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1.3.2 Defensins 
Defensins constitute another major family of AMPs in mammals. These are cationic 
peptides with a characteristic antiparallel β-sheet fold and consist of six highly 
conserved cysteine residues forming three pairs of disulfide bridges. Defensins, based 
on the size and on the alignment of the disulfide bonds are classified into α-, β-, and θ- 
defensins [130]. 
 
1.3.2.1 α- and θ- defensins 
In human, there are six α-defensins: Human neutrophil peptides (HNP)-1 to 4 and 
human defensin (HD)-5 and -6. HNPs are abundant in PMNs and thus designated as 
neutrophil peptides. These peptides are also expressed in additional immune cells such 
as monocytes, NK cells, B cells and γδ T cells [103]. Paneth cells at the base of the 
small intestinal crypts are the main source of HD-5 and -6 [131, 132]. HD-5 has also 
been detected in female genital tract [133].  
 θ- defensins, identified only in non-human primates, are 18 residues long, 
cyclized peptides, with sequences closely related to the non-cyclized α-defensins [130]. 
Similar to cathelicidins, α-defensins (and also θ-defensins) are produced as 
preproprotein followed by removal of pre- and pro-sequences to generate active 
peptides [130]. 
 
1.3.2.2 β- defensins 
Four β-defensins have so far been characterized in human: Human β-defensin (HBD)-1 
to 4. HBD-1 was isolated from human blood filtrate [134] and HBD-2 and -3 were 
isolated from psoriatic scales [135, 136]. HBD-4 was identified, based on screening of 
genomic sequences and a synthetic peptide was made and functionally characterized 
[137]. However, natural HBD-4 has not yet been isolated. Twenty-eight additional 
genes encoding HBDs have been identified in the human genome [138]. In contrast to 
α- and θ-defensins, the precursors of β-defensins have a very short pro-sequence 
separating the signal and mature peptide regions [130]. 
HBDs are predominantly expressed in epithelial cells but also in leukocytes. HBD-
1 is expressed constitutively in most tissues, while expression of HBD-2, -3 and -4 is 
often induced. However, HBD-1 expression can also be induced, for example by IFN-γ 
or by LPS in monocytes, macrophages and dendritic cells [139]. Induction of HBD-2 is 
also observed in these cells. Expression of HBD-2 and -3 is augmented in keratinocytes 
by S. aureus and IL-22 [124, 140]. In respiratory epithelial cells, HBD-2 expression is 
upregulated by Pseudomonas aeruginosa, tumor necrosis factor- α (TNF-α) and IL-1β 
[141]. TNF-α and heat-inactivated P. aeruginosa and S. aureus upregulate the 
expression of HBD-3 in primary keratinocytes and tracheal epithelial cells [136]. 
Expression of HBD-3 is also increased by the growth factors, IGF-1 and TGF-α, in 
keratinocytes [127]. HBD-4 expression is upregulated in primary respiratory epithelial 
cells after infection with P. aeruginosa and Streptococcus pneumoniae [137]. 
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1.3.3 Functions of LL-37, β-defensins and their orthologues 
 
1.3.3.1 Antimicrobial activity and microbial resistance 
LL-37 is active against the gram negative bacteria P. aeruginosa, Salmonella 
typhimurium, E.coli, Proteus mirabilis, Neisseria gonorrhoeae, N. meningitidis [112, 
126, 142, 143] and the gram positive bacteria S. aureus, Staphylococcus epidermidis, 
Listeria monocytogenes and GAS [106, 142]. LL-37 also displays inhibitory activity 
against the yeast Candida albicans [142] and some viruses [144-146]. The antibacterial 
activity of LL-37 positively correlates with the extent of helicity of the peptide, which 
in turn depends on the ionic environment and pH [85]. Helical content of LL-37 is 
enhanced with increasing concentration of salt and/or increasing pH and it adopts the α-
helical conformation in physiological salt solution. However, Turner et al. have shown 
that certain organisms such as methicillin-resistant S. aureus, P.mirabilis and C. 
albicans are resistant to LL-37 at high salt concentration but are sensitive at low-salt 
media [142]. mCRAMP exhibits antimicrobial activity against GAS [106], 
uropathogenic E. coli [112], N. meningitidis [126] and vaccinia virus [146]. S. 
typhimurium survives and replicates inside macrophages derived from mCRAMP-
deficient mice, but the replication is impaired in wild type macrophages [129]. N. 
meningitidis is sensitive to rCRAMP [147]. Rabbit CAP-18 exerts antimicrobial 
activity against P. aeruginosa, E.coli, S. aureus, methicillin-resistant S. aureus, S. 
pneumoniae and S. typhimurium [148, 149]. Moreover, LL-37 hampers the ability of 
uropathogenic E.coli to form curli-mediated biofilm [150]. 
HBD-1 displays antimicrobial activity against P. aeruginosa and E.coli [151]. 
HDB-2 is bactericidal for P.aeruginosa, S.aureus and antibiotic-resistant E.coli, 
Klebsiella pneumoniae and P. mirabilis [152]. HBD-3 is active against P. aeruginosa, 
E. coli, Streptococcus pyogenes, S. aureus (including multidrug-resistant strains) and 
vancomycin-resistant Enterococcus faecium [136].  P. aeruginosa and Staphylococcus 
carnosus are susceptible to HBD-4 [137]. Although all HBDs show antibacterial 
activities, the activity of HBD-1, -2 and -4 are inversely proportional to salt 
concentration [137, 151, 152], while HBD-3 is quite stable in a wide range of salt 
concentrations [136]. The formation of stable dimer or oligomer in solution has been 
suggested for the salt-resistance of highly cationic HBD-3 [153]. In addition to 
enhanced salt resistance, Midorikawa et al. have demonstrated that the antibacterial 
activity of HBD-3 against S. aureus is much stronger than that of HBD-1 or -2 [124]. 
However, platelet-derived HBD-1 displays potent antimicrobial activity against S. 
aureus and additionally induces PMNs to form NETs [154]. Recombinant HBDs 
possess antifungal activities against Candida spp. and the activity is more prominent 
for HBD-2 and -3 than HBD-1 [155]. Interestingly, after reduction of disulphide 
bridges, HBD-1 exerts potent antimicrobial activity against C. albicans and against 
anaerobic commensals of Bifidobacterium and Lactobacillus species [156]. Natural 
HBD-3 also impede Candida albicans [136]. HBD-2 and -3 inhibit HIV-1 replication 
in oral epithelial cells [157], while HBD-3 exhibits anti-viral activity against vaccinia 
virus [158] and prevent cervical epithelial cells from herpes simplex virus (HSV) 
infection [159]. Recombinant HBD-1 and -2 have antiparasitic activity against 
Cryptosporidium parvum sporozoites [160]. 
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Synergistic or additive effects between HBDs and with LL-37 or other AMPs 
have also been documented. LL-37 and HBD-1 kill H.pylori individually and together 
these peptides reveal a synergistic effect [111]. LL-37 together with HBD-2 or -3 
constitute synergistic effect against S. aureus, while the effect was additive with HBD-
1 [124]. Combination of HBD-1, -2 and -3 shows additive effect against S.aureus 
[124]. HBD-4 exhibits synergy with lysozyme and strong additive effect with HBD-3 
against E. coli and S. carnosus [137]. 
Several pathogenic microorganisms have evolved resistance to AMPs. Multiple 
strategies used by the pathogens to avoid antimicrobial effect of LL-37, HBDs and their 
orthologues are briefly discussed here.  
(i) Pathogens can resist AMP activity by suppressing AMP expression. Shigella spp., 
Vibrio cholerae and enterotoxigenic E. coli (ETEC) downregulate LL-37 and HBDs in 
iEC [30, 31, 161]. LL-37 is also downregulated by N. gonorrhoeae in cervical 
epithelial cells [143]. Capsular K. pneumoniae impedes the expression of HBD-2 and -
3 in airway epithelial cells [162]. 
(ii) Several bacteria such as P. aeruginosa, P. mirabilis, Porphyromonas gingivalis, S. 
aureus, S. pyogenes and Enterococcus faecalis secrete proteases that degrade LL-37 
[163-166]. Secreted proteases from P. mirabilis and P.gingivalis also degrade HBD-1 
and HBD-3, respectively [164, 167]. Cell-wall or cell-membrane associated proteases 
of enterohemorrhagic E. coli (EHEC) and Yersinia pestis cleave LL-37 [168, 169]. 
mCRAMP is degraded by cell membrane associated proteases of Citrobacter 
rodentium [170].  
(iii) Secreted molecules other than proteases such as streptococcal inhibitor of 
complement (SIC) from S. pyogenes binds and traps LL-37 extracellularly [171]. 
(iv) Capsular polysaccharide (CPS) of K. pneumoniae limits the binding of HBD-1 and 
other AMPs to the bacterial surface [172]. CPS of N. meningitidis can resist LL-37, 
mCRAMP, HBD-1 and -2 [173, 174]. Notably, sublethal concentrations of AMPs have 
been demonstrated to augment transcription of the capsule genes [172-174]. 
Sequestration of HBD-3 and LL-37 by elaborated polysaccharide matrices of S. 
epidermidis also inhibits the antibacterial activity of these peptides [175, 176]. In 
addition, curli fimbriae of uropathogenic E coli bind and increase bacterial resistance to 
LL-37 and mCRAMP [150].  
(v) Bacteria also resist AMP activation by modification of cell surface. Incorporation of 
D-alanine into teichoic acid of S aureus reduces negative charge of the cell wall and 
repels cationic peptides including mCRAMP [177]. Substitution of negatively charged 
cell membrane constituents of S aureus with cationic lysyl- phosphatidylglycerol 
confers resistance to LL-37 and HBD-3 [178]. Modification of lipid A head groups 
such as addition of 4-aminoarabinose (Ara4N) to the phosphate group in P. aeruginosa 
renders the pathogen resistant to HBD-1, HBD-2, LL-37 and CAP-18 [179]. N. 
meningitidis modifies lipid A head groups of lipooligosaccharide (LOS) with 
phosphoethanolamine and inhibits LL-37 interaction to the cell membrane [180]. Group 
B Streptococcus (GBS) can resist inhibitory activity of mCRAMP and LL-37 through 
cell surface-associated penicillin-binding protein 1a (PBP1a) without modifying 
bacterial surface charge or peptidoglycan cross-linking [181]. 
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(vi) Removal of peptides by efflux pump makes N. gonorrhea and N. meningitidis 
resistant to LL-37 [180, 182]. Deletion of genes encoding AcrAB efflux pump in K. 
pneumoniae enhances bacterial sensitivity to defensins [183]. On the other hand, H. 
influenza imports LL-37 and HBD-3 by utilizing the Sap A (sensitivity to antimicrobial 
peptide A) transporter into the cytoplasm and subsequently degrades these peptides 
[184]. Interestingly, bacteria lacking a functional Sap permease complex accumulates 
AMPs in the periplasm of the outer membrane, whereas parental cells accumulate them 
in the cytoplasm and periplasm.  SapA, thus protects cytoplasmic membrane from 
AMP activity [184]. 
(vii) Bacteria can exploit host systems for their resistance to AMPs. Attachment of N. 
meningitidis to epithelial cells and binding of polyamines to the outer surface of N. 
Gonorrhea contribute to their resistance to LL-37 [174, 185]. 
 
1.3.3.2 Additional functions 
In addition to antimicrobial activity, numerous immunomodulatory and tissue 
homeostatic functions have been attributed to LL-37, HBDs and their orthologues. LL-
37 exhibits chemotactic activity to PMNs, monocytes and T cells via binding to the 
formyl peptide receptor like-1 (FPRL-1) on the surface of these cells [103, 186]. 
mCRAMP also chemoattracts leukocytes by utilizing FPRL-1 or its mouse homologue 
formyl peptide receptor-2 [187]. HBD-1 displays chemotaxis of monocyte-derived 
dendritic cells (DCs) [188]. HBD-2 chemoattracts immature DCs and memory T cells 
through CCR6 receptor [189]. The chemotaxis of leukocytes by HBD-2 and -3 and 
their mouse orthologues MBD-4 and -14 involves CCR2 receptor [190]. LL-37 and 
HBD-2 display chemotactic activity to mast cells [191, 192]. Moreover, LL-37 and 
HBDs induce chemokine and cytokine secretion from different cell types [193]. These 
immunomodulatory functions may contribute to resolution of infection but may also 
give rise to inflammatory disorders. For instance, LL-37 can stimulate the synthesis of 
the proinflammatory lipid mediator leukotriene B4 from PMNs and form a positive 
feedback loop to perpetuate the inflammatory responses [194]. However, LL-37 and 
defensins also exert anti-inflammatory responses by direct binding and neutralization of 
microbial components, by inhibiting the production of pro-inflammatory mediators or 
by inducing anti-inflammatory cytokines [88, 193, 195-197]. In addition, rabbit CAP-
18 was discovered as a LPS binding protein [89]. 
LL-37 mediates wound healing of skin and airway epithelia through 
inducing epithelial cell proliferation and migration [92, 95]. Intestinal epithelial barrier 
integrity is also maintained and reestablished by LL-37 [94]. LL-37 promotes 
cutaneous wound neovascularization through angiogenic activity, which involves 
increased proliferation of endothelial cells and subsequent vessel-like structure 
formation [93]. Similarly, HBD-2 stimulates chemotaxis, proliferation, capillary-like 
tube formation and enhances the speed of wound closure of human umbilical vein 
endothelial cells [91].  
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1.3.3.3 Physiological relevance 
The physiological relevance of LL-37, HBDs and their orthologues has been 
demonstrated in human diseases as well as in animal models. An abundant expression 
of LL-37, HBD-2 and -3 is observed in psoriatic lesions of human skin compared to 
healthy skin, while in atopic dermatitis (AD), the induction is minor [122, 198]. The 
observed difference in the expression of these three AMPs is well correlated with the 
fact that eczemas of AD are highly susceptible to recurrent infections, while psoriatic 
lesions are rarely infected [199]. Moreover, a subset of AD patients with disseminated 
infection with HSV was demonstrated to exhibit significantly lower expression of LL-
37, HBD-2 and -3 in skin biopsies compared to uncomplicated AD [200, 201]. The 
specific role of LL-37 orthologue in skin defense has been evaluated in mCRAMP 
knock-out (KO) mice. Compared to wild type mice (Cnlp+/+), mCRAMP KO mice 
(Cnlp-/-) are more susceptible to HSV, vaccinia virus and GAS infection [146, 200, 202, 
203]. However, LL-37 has also been implicated in the pathogenesis of psoriasis. By 
forming complex with self-DNA or -RNA, LL-37 triggers abrupt activation of dendritic 
cells via toll-like receptors (TLRs) [204, 205]. LL-37 and its shorter forms are 
expressed abnormally in the facial skin of individuals with rosacea, stimulating skin 
inflammation [206]. 
Cystic Fibrosis (CF) is a lethal genetic disease caused by a mutation in the gene 
encoding CF transmembrane conductase regulator (CFTR). Patients with CF are 
susceptible to recurrent infections in airway surface epithelia (ASE) mainly by 
P.aeruginosa and S. aureus. CFTR dysfunction has been proposed to facilitate 
infections of ASE in several different manners [207]. One theory is the accumulation of 
excessive salt in airway surface fluid (ASF), leading to reduced antimicrobial activity 
of HBD-1 [151]. The antimicrobial activity of LL-37 is also compromised in CF lung 
fluids because of complex formation between LL-37 and glycosaminoglycans [208]. 
However, overexpression of LL-37/hCAP-18 in CF xenograft model was shown to 
restore the antimicrobial activity of the ASF [209]. Transgenic mice expressing LL-
37/hCAP-18 in the respiratory tract was also demonstrated to decrease bacterial load 
and inflammatory responses following pulmonary challenge with P. aeruginosa [210]. 
Deletion of the gene encoding MBD-1in a mouse model of influenza infection was 
shown to stimulate an early inflammatory response in lung, leading to early lose of 
body weight and faster death of the mice [211]. 
The importance of LL-37 has also been exemplified in two rare congenital 
disorders. Patients with Morbus Kostmann, a neutropenic disease, are susceptible to 
recurrent infections and periodontitis. Treatment with granulocyte colony stimulating 
factor (GM-CSF) restores the level of PMNs but does not prevent infections, indicating 
functional deficiencies of PMNs. In fact, in a study by Putsep et al., PMNs were found 
to be deficient in LL-37 and HNP1-3 [212]. In addition, LL-37 could not be detected in 
saliva and plasma of the patients [212]. Patients with neutrophil specific granule 
deficiency (SGD) also suffer from frequent bacterial infections. Low expression of LL-
37 and other antimicrobial peptides/proteins may explain the susceptibility of these 
patients to infections [213]. 
The level of HBD-3 is significantly reduced in gingival crevicular fluid (GCF) 
of periodontitis patients, compared to healthy controls and is inversely proportional to 
bacterial colonization and the severity of the disease [214].  
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Systemic expression of LL-37/hCAP-18 in transgenic mice was shown to 
confer protection from induced sepsis [210]. Furthermore, rat receiving intraperitoneal 
LL-37 could prevent LPS-induced sepsis [215]. 
Low immunoreactivity of hCAP-18 in chronic skin ulcers of patients, as 
opposed to acute wounds reflects the physiological significance of LL-37/hCAP-18 in 
wound healing [92]. 
A combined effect of MBD-2 and -3 was shown in a mouse model of P. 
aeruginosa keratitis. Silencing MBD-2 or -3 individually led to increased bacterial load 
and elicited differential effects on disease pathology. However, silencing both genes 
elevated the bacterial load and inflammatory responses [216]. 
 
1.3.4 Induction of LL-37, β-defensins and their ortholouges by extrinsic 
compounds 
The expression of cathelicidins and defensins can be induced by different extrinsic 
compounds in a cell and tissue specific manner. Butyrate, a short chain fatty acid 
(SCFA), induces the expression of LL-37 preferentially in colonic epithelial cells [109, 
217-220] and in lung epithelial cells [221]. Butyrate-induced LL-37 expression 
correlates with the increased antimicrobial activity of the colonic epithelial cell lysate 
[218]. Butyrate is a histone deacetylase inhibitor (HDACi), promoting acetylation of 
histones. Histone acetylation has been proposed for the induction of CAMP transcript 
by unwinding the chromatin structure, facilitating binding of transcription factors at the 
promoter region [220, 221]. In agreement with this, a synthetic HDACi, trichostatin A 
(TSA) induces CAMP expression [220]. Binding of transcription factors such as 
vitamin D receptor (VDR), putative activator protein 1 (AP-1) and PU.1 of the Ets 
family to the corresponding binding sites at the promoter region has been demonstrated 
for butyrate-induced expression of CAMP gene [219, 221, 222]. Furthermore, 
Inhibition of different mitogen-activated protein kinases (MAPK) hinders CAMP 
induction by butyrate [217, 219, 221]. Butyrate also induces HBD-2 in monocytes 
[218]. 
Our group has found that phenylbutyrate, an analogue of butyrate upregulates 
the expression of the CAMP gene in different epithelial cell lines and also in monocytes 
[223]. The involvement of MAPK signaling cascade was demonstrated for this 
induction. However, PB could not mediate significant changes in histone acetylation at 
the CAMP proximal promoter, although an increase in genome-wide histone acetylation 
was observed. Interestingly, inhibition of protein synthesis by cycloheximide (CHX) 
blocked PB and butyrate mediated CAMP gene induction. These results indicate no 
direct effect of PB on the chromatin structure at the CAMP gene promoter. Rather, 
enhanced histone acetylation indirectly induces the CAMP gene by promoting 
expression of genes, encoding critical regulatory factors. Gene encoding HBD-1 was 
also induced by PB in lung epithelial cells, but was downregulated in PB-stimulated 
monocytes [223]. 
 The hormonal form of vitamin D3 (1, 25- dihydroxyvitamin D3) and its 
analogues upregulate the CAMP gene expression in keratinocytes, oral/ lung/colonic 
epithelial cells, monocytes, PMNs, bone-marrow (BM) derived macrophages and fresh 
BM cells [224, 225]. Gene encoding HBD-2 is also induced by vitamin D in 
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keratinocytes and in oral/ lung epithelial cells [224]. The induction is mediated through 
interaction between VDR and a consensus vitamin D response element (VDRE) in the 
promoter of the CAMP gene [224, 225]. Since, VDRE is absent in the Cnlp gene, LL-
37 induction by vitamin D does not occur in murine cells [225]. A synergistic effect of 
LPS and vitamin D was observed on CAMP gene expression in PMNs, which 
correlated with increased antimicrobial activity of PMNs [224]. In human 
macrophages, activation of TLRs upregulates VDR and the vitamin D1 hydroxylase 
genes, leading to the induction of LL-37 with subsequent killing of intracellular 
Mycobacterium tuberculosis [226]. Interestingly, tuberculosis susceptible African-
American individuals have low serum levels of 25-hydroxyvitamin D3 and hence are 
less efficient in inducing the expression of LL-37 [226].  
Butyrate and vitamin D have tissue specific preference for colonic epithelial 
cells and keratinocytes, respectively [218]. However, butyrate or TSA can amplify the 
vitamin D-induced expression of LL-37 in keratinocytes via increased acetylation of 
histones [227]. A synergistic effect of PB and vitamin D was also observed on CAMP 
gene expression in lung epithelial cells [223]. 
L-isoleucine promotes HBD-2 expression in pulmonary epithelial cells [228]. In 
lung extract of M. tuberculosis infected mice, significant induction of MBD-3 and -4 
after intratracheal administration of L-isoleucine was demonstrated to correlate with 
decreased bacillary loads and tissue damage [228]. 
Additional components such as lithocolic acid (LCA) and trace metal zinc 
induce LL-37 expression in colonic epithelial cells and LCA was shown to have 
additive effect with butyrate [222, 229]. 
 
1.4 BUTYRATE IN INTESTINAL INFLAMMATION 
Short chain fatty acids (SCFAs), particularly acetate, propionate and butyrate are 
produced through fermentation of mainly undigested dietary carbohydrates and other 
dietary and endogenous substrates by the colonic flora [230, 231]. SCFAs, 
predominantly butyrate are rapidly absorbed and metabolized by the colonic mucosa 
and provide energy for colonocytes [231]. Butyrate exerts various additional effects, 
influencing colonic health such as proliferation and differentiation of colonocytes, 
epithelial barrier function, transepithelial ion transport, visceral perception and 
intestinal motility. Moreover, butyrate affects regulation of immunity, inflammation 
and oxidative stress [230]. Several extra-intestinal effects of butyrate have also been 
reported [230]. 
The role of butyrate in intestinal inflammation has been investigated in 
several intervention studies on patients with inflammatory bowel disorders. In a 
randomized, single-blind controlled trial, administration of butyrate enema in patients 
suffering from distal ulcerative colitis (UC) resulted in an improvement in clinical, 
endoscopic and histologic features [232]. In an open-labeled study, patients with distal 
UC, refractory to available rectal therapy and to oral sulfasalazine or mesalamine (also 
known as mesalazine or 5-ASA), exhibited 40% complete response rate and an overall 
60% response rate after receiving butyrate enemas [233]. In a randomized, double-
blind, placebo-controlled trial, Vernia et al. found a significantly better improvement of 
disease activity index (DAI) and overall clinical index of UC after treatment with 
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combination of oral sodium butyrate and oral mesalazine compared to mesalazine 
treatment alone [234]. The same group later demonstrated a similar effect of topical 
administration of butyrate together with oral mesalazine in the treatment of UC [235]. 
In a randomized, double-blind, cross-over trial, significant remission of clinical score 
and majority of individual clinical, endoscopic and histological parameters of acute 
radiation proctitis (ARP) was observed after topical treatment with butyrate but not 
with saline [236]. When the treatment regimen was switched to butyrate, the majority 
of the previously placebo-treated patients had remedial of symptoms. On the other 
hand, one-third of the previously butyrate-treated patients exhibited a relapse of ARP 
symptoms, when switched to saline [236]. In another study, significant decrease in DAI 
of UC by butyrate enema correlated with significant reduction of PMNs in crypt and 
surface epithelia as well as lymphocytes/plasma cells in lamina propria (LP) of the 
rectal mucosa [237]. Interestingly, nuclear translocation of nuclear factor κβ (NF-κβ) 
was observed in almost all LP macrophages before treatment, which was reduced after 
butyrate treatment. These findings indicate that butyrate exert anti-inflammatory 
response in UC, in part by reducing production of inflammatory mediators through 
inhibition of NF-κβ activation [237]. Patients with mildly to moderately active Crohn’s 
disease (CD) experienced significant improvement in DAI, endoscopical and 
histological score, and significant reduction of mucosal level of NF-κβ and IL-1β after 
receiving enteric-coated butyrate tablets [238]. When colonic biopsy specimens and 
isolated lamina propria mononuclear cells (LPMC) from CD patients were cultured 
with butyrate, reduction of proinflammatory cytokines and inhibition of nuclear 
translocation of NF-κβ was observed [239]. Similar effect of butyrate was observed in 
LPS-stimulated peripheral blood mononuclear cells (PBMC) [239]. 
In an animal model of chemically-induced colitis, clinical recovery, 
improvement of colonic damage score and electrolyte absorption after butyrate enema 
treatment correlated with reduced myeloperoxidase (MPO) activity[240]. Furthermore, 
IFNγ/STAT1 signaling, which plays an important role in the pathogenesis of IBD, was 
inhibited by butyrate in colonic epithelial cell lines [241]. 
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2 RATIONALE, HYPOTHESIS AND AIMS OF THE 
STUDY 
The emergence of multidrug-resistant bacterial strains due to uncontrolled use of 
antibiotics is a serious threat for the management of infectious diseases. Adverse effects 
of antibiotic treatment such as disruption of the normal gut flora and release of toxic 
microbial components further worsen the situation.  Therefore, development of novel 
antimicrobial therapies is warranted. AMPs with a broad spectrum of antimicrobial 
activity complemented with immunomodulatory activities are attractive therapeutic 
candidates. AMPs are bactericidal rather than bacteriostatic and in contrast to 
traditional antibiotics, attack multiple targets within the bacteria, leading to low 
propensity for the development of bacterial resistance (reviewed in [242]). Although, 
pathogens have developed mechanisms to resist AMP activity, the resistance appears to 
be modest compared to conventional antibiotics [242]. Moreover, AMPs can be utilized 
as adjunct therapy to current antibiotics in a synergistic or additive manner. The role of 
AMPs in tissue homeostasis such as angiogenesis and wound healing may also be 
exploited, when using these peptides as anti-infective drugs. 
Utilizing AMPs as template, antimicrobial drugs have been synthesized. 
However these drugs have certain drawbacks for therapeutics usage. In addition to high 
production cost, systemic delivery of these drugs is limited by poor pharmacokinetics, 
due to their susceptibility to proteases and unknown toxicity profile against the host 
cells [242]. Since peptide-based drugs are unlikely to be resorbed from the 
gastrointestinal tract, oral administration is also not feasible. Although, several 
approaches have been made to overcome these limitations, to date only few of these 
drugs have undergone clinical trials [242]. Most of the drugs in clinical trials, have 
been restricted to topical applications and only gramicidin S and polymyxin B, which 
are based on bacterial AMPs, have been approved so far by FDA for topical use. 
A promising alternative option would be the induction of endogenous 
AMPs by topical or systemic administration of extrinsic compounds. With the advent 
of tissue preferring stimulants, it is possible to induce abundant amount of AMPs at the 
sites of infection without systemic accumulation, reducing the risk of adverse systemic 
reactions. It is also possible to stimulate a battery of AMPs by using very small number 
of stimulants, making the approach more feasible than delivering several AMPs 
together. Inducers, such as butyrate, vitamin D, zinc, LCA and isoleucine are 
synthesized by the host itself or obtained from the diet and are required for 
physiological functions. These natural compounds or their analogues are readily 
available at low cost, making this strategy cost-effective and relatively safe. 
Phenylbutyrate is even a FDA- approved drug for urea cycle disorder.The induction 
approach may particularly be important, when pathogens downregulate AMPs at the 
local site of infection as a means of immune evasion. 
In a previous study, our group found that the expression of LL-37 and HBD-1 is 
downregulated in large intestinal epithelial cells of patients, during acute shigellosis, 
thereby facilitating bacterial invasion [30]. We hypothesized that this downregulation 
could be counteracted via induction of AMPs by using butyrate or phenylbutyrate. This 
counteraction would correlate with the improved clinical, histological and 
microbiological features of shigellosis, as demonstrated in a rabbit model by colonic 
infusion of SCFA mixture (acetate, propionate and butyrate) [243]. Since, patients with 
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shigellosis are often prone to secondary respiratory infections [2-4], we assumed that 
Shigella infection would also reduce AMP expression in respiratory epithelia, which 
could be counteracted by treatment with butyrate or phenylbutyrate. As antibiotics 
exhibit different immunomodulatory effects [244], the expression of AMPs might also 
be affected by antibiotics. 
 
The aims of the thesis were: 
 
I. To investigate the effect of oral administration of sodium butyrate (NaB) in 
a rabbit model of shigellosis on clinical outcome, intestinal inflammation, 
bacterial load in stool, the expression of CAP-18 in large intestinal mucosa 
and the processing of CAP-18 in stool. 
 
II. To evaluate the efficacy of NaB enema as adjunc therapy to antibiotics in 
patients with shigellosis by analyzing clinical, histopathological and 
microbiological outcome, the expression of LL-37 in large intestinal 
mucosa and the levels of released LL-37, HBD-1 and HBD-3 in stool. 
 
III. To study the effect of oral sodium-4-phenylbutyrate (PB) treatment in a 
rabbit model of shigellosis on clinical consequences, bacterial shedding in 
stool, CAP-18 expression in the large intestinal mucosa and the processing 
of CAP-18 in stool. Moreover, the effect of PB and NaB on CAP-18 
expression in lung and tracheal mucosa were examined. 
 
IV. To determine, whether antibiotics affect the expression of AMPs in colonic 
epithelial cells in vitro and in vivo and hence contribute to the antibiotic- 
associated diarrhea caused by Clostridium difficile. 
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3 METHODOLOGY 
The methods utilized in this thesis are listed below. Detailed description of the methods 
can be found in the papers as referred. 
 
1) Animal model (rabbit model of shigellosis) :  Paper I, III, IV 
2) Administration of NaB/saline in patients :  Paper II 
3) Clinical investigations and endoscopic evaluation   
of inflammation in the rectal mucosa of patients 
 
:  Paper II 
4) Biopsy collection and processing for              
histology/immunohistochemistry 
 
:  Paper I, II, III, IV 
5) Bacterial counts in stool :  Paper I, II, III 
6) Inhibition zone assay (antibacterial assay)             
and depletion of antibacterial activity 
 
:  Paper I 
7) In vitro bacterial killing assay :  Paper I, IV 
8) Stool extraction :  Paper I, II, III 
9) Cell culturing (HT-29) and stimulation :  Paper IV 
10) Histone extraction :  Paper IV 
11) Enrichment of peptide/protein :  Paper I, III, IV 
12) Western blot analysis :  Paper I, III, IV 
13) Real-time PCR :  Paper I, III, IV 
14) Microarray analysis :  Paper IV 
15) Histology :  Paper I, II 
16) Immunohistochemistry :  Paper I, II, III, IV 
17) Image analysis :  Paper I, II, III, IV 
(Paper III supporting 
information S1 for details) 
18) Immunofluorescence staining :  Paper IV 
19) Enzyme-linked immunosorbent assay (ELISA) :  Paper II 
20) Measurement of butyrate levels in blood :  Paper III 
21) Biosafety evaluation of NaB or PB treatment :  Paper I, II,III 
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4 RESULTS AND DISCUSSION 
 
4.1 CATHELICIDIN INDUCTION BY BUTYRATE OR PHENYLBUTYRATE 
TREATMENT CORRELATES WITH IMPROVED 
CLINICOPATHOLOGICAL AND MICROBIOLOGICAL FEATURES OF 
SHIGELLOSIS (PAPER I-III). 
In paper I, a non-surgical rabbit model of shigellosis was developed according to 
Etheridge et al. [245] to investigate the therapeutic potential of sodium butyrate (NaB). 
Rabbits infected with S. flexneri 2a developed human-like dysenteric symptoms such as 
thick liquid stool with mucus and occasional blood, decreased body weight, transient 
fever, lethargy and anorexia, usually within 24 hours of infection. Hence, this 
experimental model of shigellosis was suitable for therapeutic intervention. The 
efficacy of NaB as adjunct therapy to antibiotics was then evaluated in adult patients 
with shigellosis in a double-blind, randomized clinical trial (paper II). However, oral 
administration of NaB in human is limited by its characteristic bad smell. Therefore, in 
paper III, we investigated the therapeutic effect of sodium-4-phenylbutyrtae (PB), an 
odorless butyrate analogue in the same rabbit model of shigellosis. 
 
4.1.1 Effect of butyrate or phenylbutyrate treatment on the expression 
of cathelicidins and β-defensins in gut mucosa and lumen during 
shigellosis (paper I-III) 
By utilizing immunostaining technique, CAP-18 peptide/protein (designated for mature 
CAP-18 peptide/proform) expression was largely detected in the surface epithelia (SE) 
of colonic and rectal mucosa in healthy rabbits (paper I and III). The expression was 
very low in lamina propria (LP). When the rabbits were infected with Shigella, a 
significant downregulation of CAP-18 peptide/protein was observed in colonic and 
rectal SE. However, numerous LP cells were positive for CAP-18 peptide/protein after 
Shigella infection. These results confirm our previous findings, where we showed 
downregulation of LL-37/hCAP-18 in the epithelia and influx of LL-37/hCAP-18 
positive PMNs and macrophages in LP of the rectal mucosa in patients with acute 
shigellosis [30]. In that study, suppression of the CAMP gene and the gene encoding 
HBD-1 in gut biopsies and in colonic epithelial and monocytic cell lines was also 
demonstrated. Bacterial plasmid DNA was indicated as the potential mediator of this 
downregulation [30]. Reduced expression of the CAMP gene and the gene encoding 
HBD-3 in Shigella- infected colonic epithelial cells was also reported in a later study 
[31]. The authors suggested a set of virulent plasmid-encoded effectors, regulated by 
the MxiE transcriptional activator, being involved in this downregulatory process. 
 Oral treatment of Shigella-infected rabbits with NaB restored CAP-18 
peptide/protein expression in colonic and rectal SE (paper I). On the other hand, CAP-
18 peptide/protein positive cells in LP were decreased considerably after NaB  
treatment, suggesting a low influx of inflammatory leukocytes. Similar to NaB 
treatment, oral PB treatment counteracted CAP-18 peptide/protein expression in the 
rectal SE (paper III). In addition to epithelial induction, NaB or PB treatment prompted 
the secretion and/or processing of CAP-18 in intestinal lumen. Western blot analysis of 
stool extracts revealed CAP-18 proform in healthy and majority of the infected rabbits. 
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NaB treatment resulted in the appearance of processed CAP-18 peptide in stools, 
collected every day during the treatment period (paper I). The proform was also present 
in the beginning of the treatment, which disappeared later. By PB treatment, the level 
of proform was elevated and low level of processed CAP-18 peptide was detected 
throughout the treatment regimen (paper III). Thus, we speculated that NaB or PB 
might activate some proteases that cleaved the CAP-18 precursor to generate the 
mature peptide in the gut. The processing enzyme has not been identified so far. 
However, in a recent microarray analysis (paper IV, not published), we found an 
induction of the gene encoding kallikrein-1 in NaB-stimulated colonic epithelial cell 
line. Kallikerin-5 was previously shown to process hCAP-18, generating LL-37 and 
several other truncated peptides in keratinocytes [118]. Mature CAP-18 peptide was 
also detected in the stool of one infected rabbit, which most probably originated from 
the infiltrating immune cells. The size difference between peptides derived from the 
infected rabbit and the treated rabbits might reflect the different processing of the 
precursor proteins in different cell types (epithelial or immune cells). Further studies 
will be needed to validate this hypothesis. 
 Low expression of LL-37/hCAP-18 in the rectal epithelia was observed 
in Shigella- infected patients at the acute stage (day 1) (paper II). However, ample level 
of LL-37/hCAP-18 was detected in stool extract by ELISA on day 1, which was 
consistent with the high frequency of inflammatory cells in stool. Administration of 
NaB as enema significantly augmented LL-37/hCAP-18 expression in the rectal 
epithelia on day 7 compared to that in placebo treated patients. Levels of LL-37/hCAP-
18 in stool went down significantly in both treatment groups from day 4 onwards, 
reflecting recovery from infection and consequent reduction of inflammation due to 
antibiotic treatment (discussed later). However, concentration of LL-37/hCAP-18 in 
stool remained significantly higher on day 4 and 7 in NaB-treated patients compared to 
placebo-treated patients. Large intestinal epithelia could be the source of LL-37/hCAP-
18 during the recovery phase of the disease. No difference was eminent in the levels of 
HBD-1 and HBD-3 in stool between the NaB- and placebo- treated patients throughout 
the study period. 
 
4.1.2 Shigella count in the gut lumen after treatment with butyrate or 
phenylbutyrate (paper I and III) 
In the previous study, we proposed that the downregulation of AMPs in the epithelial 
surface of the large intestine may facilitate survival of Shigella. In fact, LL-37 peptide 
was shown to exert very efficient in vitro bactericidal activity against S. dysenteriae 
type I, S. flexneri and S.boydii in that study [30]. The in vivo significance of mCRAMP 
in reducing colonization of colonic epithelia by Citrobacter rodentium and subsequent 
systemic infection was shown in KO mice [246]. Furthermore, Sperandio et al. 
demonstrated that wild type S. flexneri strain capable of downregulating HBDs and LL-
37 in the colonic epithelial cells, progresses deeply in the mucosal layer towards 
intestinal crypt of a xenotransplant model [31]. When Shigella-infected rabbits were 
treated with NaB or PB, Shigella load in stool declined gradually over time. Release of 
mature CAP-18 in the gut lumen suggested the involvement of this peptide in 
shigellacidal activity, although there might be additional antimicrobial components in 
the the lumen. Indeed, in inhibition zone assay, stool extract of a NaB- treated rabbit 
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exhibited antibacterial activity against E. coli strain D21 and 20% of this activity was 
blocked with CAP-18 specific antibody but not with an unspecific IgY antibody (paper 
I). In line with this, 97-99% killing of S. dysenteriae type I and S. flexneri 2a was 
observed in vitro with low concentration of synthetic CAP-18 peptide (0.9 µM and 1.13 
µM, respectively). Interestingly, in the presence of 40 mM NaB, lower amount of CAP-
18 peptide were required for achieving similar killing efficiency against these two 
strains (0.68 µM and 0.9 µM, respectively). NaB alone could also kill both strains of 
Shigella, but at a very high concentration (400 mM). Thus, NaB (40 mM) worked with 
CAP-18 peptide in an additive manner to kill off Shigella. 
 
4.1.3 Clinical responses in shigellosis after treatment with butyrate or 
phenylbutyrate (paper I-III) 
Counteraction of Shigella-mediated downregulation of CAP-18 peptide/protein in gut 
epithelia and reduction of bacterial load in lumen by treatment with NaB or PB, 
correlated with the clinical recovery from shigellosis in the rabbit model (paper I and 
III). Infected rabbits treated with saline never recovered from the disease and several of 
them died within 48 to 72 hours of infection. Two rabbits died even before the start of 
the treatment. Bacteremia and consequent septic shock could be the cause of death of 
these rabbits. All rabbits survived after treatment with NaB or PB and recovered from 
the disease within 3-5 days. Reduction of liquid stool and red blood cells (RBC) in 
stool was noticeable after 24 hours and maximum recovery was achieved within 72-96 
hours of treatment. However, rabbits continued to lose body weight until 48 hours after 
infection and then started to recover. Rabbits also revived from lethargy and anorexia 
after treatment. 
In clinical trial, Shigella count in stool disappeared within 48 hours in all patients 
and no significant difference was observed in terms of clinical recovery between NaB- 
and placebo-treated patients (paper II). Since, all patients were undergoing antibiotic 
treatment, simultaneous diminution of bacterial shedding and consequent clinical 
responses in both treatment groups were not unexpected. 
 
4.1.4 Inflammatory responses in shigellosis after treatment with 
butyrate or phenylbutyrate (paper I-III) 
Reduction of CAP-18 peptide/protein positive inflammatory cells in large intestinal LP 
of NaB-treated rabbits demonstrated anti-inflammatory effect of the treatment (paper I). 
No obvious difference in CAP-18 peptide/protein expression in LP was observed 
between infected and PB-treated rabbits. Although, in patients, the efficacy of NaB 
adjunct therapy on bacteriological and clinical recovery could not be evaluated, the 
effectiveness on the reduction of inflammatory responses was manifested (paper II). 
Sigmoidoscopic examination of the rectal mucosa revealed healed/reduced 
inflammation on day 7 after NaB treatment compared to day 1 in 11 out of 15 patients 
(73.3%). Notably, 9 patients (60%) with mild (n=4), moderate (n=2) or severe (n=3) 
inflammation on day 1 had completely healed mucosa on day 7. In contrast, in placebo-
treated group, 6 out of 11 patients (54.5%) showed reduction of rectal inflammation on 
day 7 and complete healing was observed only in 4 patients (36%), who presented mild 
(n=3) or moderate (n=1) inflammation on day1. By histological analysis of the rectal 
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biopsies, decrease of inflammation from day 1 to day 7 was noticed in 92.8% (13 out of 
14) patients in NaB- treated group in contrast to 50% (5 out of 10) patients in placebo-
treated group, showing statistically significant difference. In NaB-treated group, normal 
histology was observed in day 7 biopsies from 11 patients (78.6%), who had severe, 
moderate or mild inflammation (n= 1, 3 and 7, respectively) on day 1. In placebo-
treated group, only one patient (10%) was completely recovered from histological 
features of inflammation on day 7, which was significantly lower compared to NaB-
treated group. The diminished retrieval of mucosal inflammation in placebo-treated 
patients was in agreement with our previous findings, where persistence of 
proinflammatory cytokines and immune cells in the large intestinal mucosa were 
demonstrated even after clinical recovery from shigellosis [23, 25]. Moreover, an 
earlier reduction of macrophages and pus cells in stool was observed (by day-2) in 
NaB-treated patients than that in the placebo-treated patients.  Although the levels of 
proinflammatory cytokines, IL-8 and IL-1β in stool declined over time in both 
treatment groups, the reduction was higher in NaB-treated patients compared to 
placebo-treated patients. 
Eventual reduction of macrophages, pus cells and proinflammatory 
cytokines in both groups of patients indicated that the Shigella-mediated inflammatory 
responses were reduced with the recovery from infection due to antibiotic treatment. In 
the rabbit model, NaB treatment would decrease the inflammatory responses through 
reduction of Shigella load in the gut lumen. However, earlier decline of mucosal and 
luminal inflammation in NaB-treated patients suggested additional anti-inflammatory 
effects of butyrate. Indeed, butyrate was shown previously to reduce the inflammatory 
responses in UC, CD and other inflammatory bowel disorders in patients and also in 
animal model of colitis [232-241]. Induced LL-37 and CAP-18 peptide could also 
contribute to the lessening of inflammation by neutralizing Shigella components, by 
inhibiting production of proinflammatory mediators or by stimulating anti-
inflammatory cytokines [88, 89, 193, 195, 196]. Butyrate, by stimulating colonocyte 
proliferation [247], and LL-37/CAP-18 peptide, by wound healing and angiogenic 
activities [92, 93, 95] might facilitate healing of epithelial erosion and mucosal damage 
during severe shigellosis. 
 
Overall, treatment with NaB or PB resulted in the induction of epithelial 
expression of LL-37/hCAP-18 or rabbit CAP-18 peptide/protein, secretion of mature 
active peptide in the lumen along with reduction of luminal Shigella load and intestinal 
inflammation, and recovery from clinical symptoms of shigellosis. The improvement of 
clinical, bacteriological and pathological features of shigellosis was in line with the 
previously demonstrated effects of SCFA mixture [243]. Interestingly, in a recent 
randomized clinical trial, ingestion of green banana was shown to increase luminal 
SCFAs levels in Shigella-infeced children, which correlated with clinical recovery and 
reduced severity of inflammation [248]. 
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4.1.5 Effect of butyrate or phenylbutyrate treatment on the expression 
of CAP-18 peptide/protein in the mucosa of respiratory tract 
(paper III) 
In the rabbit model of shigellosis, CAP-18 peptide/protein was also downregulated in 
the epithelia of lung and trachea, indicating a systemic effect of Shigella infection. 
Suppression of innate effector molecules during shigellosis could lead to deficient 
barrier function of the respiratory tract, facilitating invasion by opportunistic respiratory 
pathogens. In fact, earlier studies reported that children with shigellosis and persistent 
diarrhea are often susceptible to secondary respiratory infections such as pneumonia 
with a fatal outcome [2-4]. Interestingly, treatment with NaB or PB counteracted the 
downregulation of CAP-18 peptide/protein in lung epithelia, suggesting the role of 
these components in restoring chemical defense barrier of the lung. Butyrate was 
shown earlier to disseminate into blood after oral administration of NaB to mice and 
rats [249]. We could also detect butyrate in serum in particular at 30 minutes after oral 
treatment of healthy rabbits with a single dose of NaB. This finding indicated that 
orally administered NaB (or PB) after being absorbed in the intestine, reached the 
respiratory mucosa through the blood stream. Induction of CAP-18 peptide/protein 
expression in the epithelia of lung, rectum and colon after intravenous injection of 
Shigella-infected rabbits with NaB further supported the systemic distribution of these 
components. 
 
4.1.6 Effect of butyrate or phenylbutyrate treatment on the expression 
of CAP-18 transcript in the mucosa of large intestine and 
respiratory tract (paper I and III) 
In parallel to CAP-18 peptide/ protein expression, we also measured CAP-18 transcript 
in the biopsy specimens of colon, rectum, lung and trachea utilizing real-time qPCR. In 
the first study (paper I), extracts of colonic and rectal biopsies contained all layers of 
mucosa. Expression of CAP-18 transcript was very high in Shigella-infected rabbits 
compared to healthy rabbits. Immunohistochemical detection of CAP-18 
peptide/protein positive immune cells in LP during infection indicated that these 
recruited cells were the source of elevated transcript level. This hypothesis was further 
supported by the presence of highest level of CAP-18 transcript in tissues with most 
severe histological grade of inflammation. Accordingly, healing of the intestinal 
inflammation with NaB treatment coincided with the drop of CAP-18 transcript to the 
level of healthy controls. To elucidate the spatial distribution of CAP-18 transcript in 
the large intestinal mucosa, epithelial and LP cells were separated in the later study 
(paper III). Expectedly, CAP-18 transcript was augmented significantly in LP cells of 
the the gut mucosa after infection compared to healthy rabbits. However, in contrast to 
the peptide/protein level, CAP-18 transcript in epithelial cells of the colon was 
enhanced after Shigella infection, indicating a possible post-transcriptional regulation. 
Low expression of proteins despite ample accumulation of corresponding transcripts 
was also noticed earlier for several cytokines in the rectum of patients with shigellosis 
[250]. In support to these findings, Hale et al. demonstrated inhibition of protein 
synthesis in epithelial cell lines, infected with S. dysenteriae 1 or S. flexneri [251]. 
Shiga toxin or shiga-like cytotoxins were shown to be responsible for this effect. After 
initial infection, host probably produces high level of CAP-18 mRNA to strengthen the 
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innate defense against the infecting pathogens. However, pathogens may in someway 
interrupt translation to escape host defense. 
Upregulation of CAP-18 transcript in the gut mucosa of rabbit after Shigella 
infection was opposite to our earlier finding in patients with shigellosis [30]. In that 
study, we demonstrated downregulation of the CAMP gene in gut biopsies at the acute 
stage of disease (day 1, enrolment day), and the proportion of patients with this 
downregulation increased in the early recovery phase (day 11 and day 30 after 
enrolment for adult and child patients, respectively). The acute stage generally refers to 
3-5 days after the onset of diarrhea. Therefore, we could not evaluate the fate of the 
CAMP gene in patients during the very early phase of infection. On the other hand, the 
infected rabbits could not be kept alive without treatment for longer periods (e.g. a 
week) to measure CAP-18 transcript at later phase. Moreover, patients were under 
treatment with antibiotics. In a recent study (paper IV, unpublished), we showed that 
ciprofloxacin suppresses butyrate-induced expression of the CAMP gene in colonic 
epithelial cell lines within 24-48 hours of stimulation. Hence, antibiotic treatment might 
also explain the decrease of the CAMP gene in gut biopsies of patients. 
The upsurge of CAP-18 transcript after Shigella infection was also observed in the 
mucosa of lung and trachea. NaB or PB treatment normalized the Shigella-mediated 
accumulation of CAP-18 mRNA in intestinal and respiratory mucosa, while amplified 
peptide/protein expression in the epithelia. The detailed mechanisms of this post-
transcriptional regulation need to be elucidated. 
 
4.1.7 Safety profile of butyrate or phenylbutyrate treatment (paper I-III) 
To evaluate the safety profile of oral NaB or PB treatment in rabbits and humans, the 
renal (creatinine and urea) and hepatic (alanine transaminase and gamma glutamyl 
transferase) biomarkers for toxicity were assessed. Treatment of healthy rabbits with 
various doses of NaB did not affect the plasma levels of these biomarkers (paper I). A 
similar outcome was observed when healthy rabbits were treated with PB (paper III). 
Notably, levels of creatinine, urea and alanine transaminase were increased after 
Shigella infection, which was normalized after PB treatment. These findings 
demonstrated no adverse effects of oral NaB or PB treatment in rabbits, rather PB 
treatment reduced the Shigella-mediated systemic toxicity. In patients, the serum levels 
of urea, alanine transaminase, gamma glutamyl transferase were within the normal 
range after topical NaB treatment (paper II). The level of creatinine was marginally 
below the normal range in both treatment groups. Previous intervention studies also did 
not report any adverse side effects of oral (2-4 g /day for 6-8 weeks) or topical (80-100 
mM/ day for 6-8 weeks) butyrate treatment in patients with UC and CD [234, 235, 237, 
238]. Moreover, application of NaB enema (80 mM, twice daily for 4 days) in healthy 
adults did not induce histological changes in the rectal mucosa [247].  PB is a FDA 
approved drug for urea cycle disorder and is well tolerated with minimum side effects 
(www.drugs.com/cons/sodium-phenylbutyrate.html). 
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4.2 ANTIBIOTIC-MEDIATED SUPPRESSION OF ANTIMICROBIAL 
PEPTIDE INDUCTION IN COLONIC EPITHELIAL CELLS: 
IMPLICATION FOR CLOSTRIDIUM DIFFICILE ASSOCIATED 
DIARRHEA (PAPER IV) 
 
4.2.1 Effect of antibiotics on butyrate-induced expression of 
cathelicidins and β-defensins in colonic epithelial cells 
Apart from exhibiting bactericidal or bacteriostatic effects on pathogens, antibiotics 
may alter bacterial properties to facilitate efficient clearance by the host immune 
system [252]. On the other hand, release of bacterial components such as LPS, teichoic 
and lipoteichoic acids, peptidoglycan, DNA and proteins due to antibiotic treatment can 
induce proinflammatory responses in host cells [253]. In addition, several antibiotics 
directly modulate expression and functions of both innate and adaptive immune 
responses [244]. For instance, fluoroquinolones, a class of antibiotics attenuate 
proinflammatory cytokine responses in vitro and in vivo, exerting beneficial effects on 
clinical response [254]. Ciprofloxacin, a fluoroquinolone antibiotic, increases the 
phagocytosis or killing capacity of PMNs and macrophages [255, 256]. Expression of 
innate immune effectors such as prostaglandin E2, nitric oxide and receptors such as 
TLRs and CD-14 are also modulated by ciprofloxacin [257, 258]. In this study, we 
demonstrated the immunomodulatory effects of antibiotics on the expression of AMPs.  
We showed that ciprofloxacin dose-dependently suppresses butyrate- 
induced expression of LL-37 transcript and LL-37/hCAP-18 in the colonic epithelial 
cell line HT-29 after 24 or 48 hours of stimulation. However, cells stimulated only with 
ciprofloxacin did not show any obvious changes in the expression of the CAMP gene or 
LL-37/hCAP-18. In fact, quinolone antibiotics generally do not exhibit detectable 
immunomodulatory activities in the absence of co-stimulant such as endotoxins, 
cytokines or stress [259]. Moreover, induction of LL-37 or rabbit CAP-18 in colonic 
epithelial cells is physiologically relevant, as butyrate is constantly produced in the 
large intestine by the fermentation of dietary substrates [230, 231]. The in vivo 
expression of CAP-18 peptide/protein in the rectal epithelia of healthy rabbits was also 
suppressed by ciprofloxacin as revealed by immunostaining. In addition, in the rabbit 
model of shigellosis, ciprofloxacin inhibited butyrate-induced expression of CAP-18 
peptide/protein. Moreover, induction of HBD-3 but not HBD-1 transcript by butyrate 
was repressed by ciprofloxacin in HT-29 cells. No effect of NaB or combination of 
NaB and ciprofloxacin was observed on the expression of HBD-2 transcript. 
The in vitro and in vivo effects of ciprofloxacin were compared with 
pivmecillinam, a β-lactam antibiotic. Pivmecillinam did not exert any effect on the 
expression of the CAMP gene or LL-37/hCAP-18 in HT-29 cells. However, 
downregulation of CAP-18 peptide/protein was observed in the rectal epithelia of 
healthy rabbits after pivmecillinam treatment. These findings pointed to the in vivo 
activation of pivmecillinam, which is actually an orally-active prodrug. The effect of 
pivmecillinam on CAP-18 peptide/protein expression in healthy rabbits was weaker 
compared to ciprofloxacin and in Shigella-infected rabbits treated with NaB, it did not 
elicit any obvious effect. 
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To further compare between fluoroquinolones and β-lactam antibiotics, 
two additional antibiotics in each group were assessed. β-lactam ampicillin and 
ceftriaxone had no effect on butyrate-induced CAMP gene expression. On the other 
hand, ofloxacin and levofloxacin, antibiotics of the fluoroquinolone group inhibited the 
CAMP gene induction, but the effect was not significant. These two fluoroquinolone 
antibiotics are structurally very similar to each other but different from ciprofloxacin. 
While, ciprofloxacin possesses a cyclopropyl ring at position N1 of the quinolone ring, 
ofloxacin and levofloxacin lack this ring [259]. Earlier, it was shown that, quinolones 
having cyclopropyl ring display enhanced anti-leukemic and hematopoietic effects, as 
opposed to the quinolones lacking this ring [260, 261]. Presence of cyclopropyl ring 
might explain the stronger suppression of butyrate-induced CAMP gene expression by 
ciprofloxacin compared to ofloxacin and levofloxacin. 
Antibiotics of other classes such as clindamycin (a lincosamide 
antibiotic), azithromycin (a macrolid antibiotic) and isoniazid (organic compound and 
anti-tuberculosis drug) were also evaluated for the effect on CAMP gene induction. 
Only clindamycin exhibited significant suppression, but the effect was less prominent 
than ciprofloxacin. While azithromycin non-significantly inhibited butyrate-induced 
CAMP gene expression, isoniazid exerted no effect. 
 Overall, variable effects on cathelicidin induction were observed between 
antibiotics from different classes and even between antibiotics from the same class; 
only ciprofloxacin and clindamycin displayed significant effects. 
 
4.2.2 Potential mechanisms for the inhibitory effect of ciprofloxacin on 
AMP induction 
By promoting acetylation of histones, butyrate or its analogue might facilitate 
transcription of the CAMP gene [220, 221, 223]. Induced phosphorylation of histone 
H3 during interphase have been shown to activate several genes such as c-fos, c-jun, 
additional AP-1 family genes and the oncogene c-myc [262]. Moreover, association 
between phosphorylation and acetylation of H3, especially between phosphorylation at 
Ser10 and acetylation at Lys14, has been implicated for transcriptional activation [263]. 
Therefore, we analyzed acetylation of histone H3 and H4 and phosphorylation of H3 to 
investigate the epigenetic modifications, potentially responsible for the effect of NaB 
and/or ciprofloxacin (or pivmecillinam) on the expression of the CAMP gene and HBD 
transcripts in HT-29 cells. Western blot analysis of histone extract revealed enhanced 
phosphorylation of H3 at Ser10 and acetylation of H3 and H4 at Lys14 and Lys 16, 
respectively, within 2 hour of NaB stimulation that persisted up to 24 hours. 
Interestingly, ciprofloxacin inhibited induced phosphorylation of H3 in a concentration 
dependent manner at any time point investigated (2, 4, 6 and 24 hours). However, no 
effect of ciprofloxacin was observed on induced acetylation of both H3 and H4. These 
findings indicated certain epigenetic modifications of histones being involved in the 
induction of AMPs by butyrate and subsequent suppression by ciprofloxacin. In a 
previous study, butyrate was shown to augment LPS-mediated expression of the gene 
encoding cyclooxygenase-2 (COX-2) in macrophages, but butyrate alone had no effect 
[264]. In fact, in conjunction with LPS, butyrate could stimulate both phosphorylation 
and acetylation of H3 at Ser10 and Lys14, respectively, at the promoter of the COX-2 
gene. However, butyrate alone induced phosphorylation but not acetylation of H3 at the 
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COX-2 promoter, although global increase of acetylation was observed by Western blot 
analysis [264]. On the other hand, we have proposed that global modification of histone 
acetylation by PB might facilitate other genes, encoding factors that induce the CAMP 
gene [223]. Determination of gene-specific modifications of histones or other gene-
encoded factors would better elucidate the mechanisms behind our findings. When cells 
were stimulated only with ciprofloxacin, no changes in histone phosphorylation and 
acetylation was observed. Pivmecillinam alone or in conjunction with NaB displayed 
no apparent effect on histone modifications. 
 MAPK signaling pathways have been shown to be involved in butyrate 
induction of the CAMP gene [217, 219, 221] as well as histone phosphorylation [263]. 
However, we did not observe any change in the expression of phosphorylated ERK 1/2 
or p-38 MAPK at any time point after stimulation (5 minutes to 24 hours) with butyrate 
and/or ciprofloxacin (or pivmecillinam). 
 
4.2.3 Effects of butyrate and combination of butyrate and ciprofloxacin 
on the expression of additional genes in colonic epithelial cells 
Microarray analysis of extracted RNA from HT-29 cells was performed in order to find 
out the effects of butyrate alone or in combination with ciprofloxacin on a broad 
spectrum of genes. Numerous genes followed the similar pattern of expression as 
CAMP gene and gene encoding HBD-3, while some others followed the opposite 
pattern. Genes that were co-expressed with the CAMP gene or HBD-3 transcript 
included those encoding G-coupled protein receptors (GPCRs), kallikrein 1, S100 
calcium binding proteins and RNase A. GPCRs have been reported to mediate the 
function of SCFA including butyrate [265, 266] and might also regulate AMP 
expression in colonic epithelial cells upon stimulation with butyrate and/or 
ciprofloxacin. By modulating the expression of kallikrein family members, butyrate 
and also ciprofloxacin could regulate the processing and activity of LL-37 [118]. In 
agreement with our findings, doxycycline has very recently been reported to inhibit the 
generation of active LL-37 by suppressing kallikrein-related peptidases [267]. 
Members of the S100 calcium binding proteins and RNase superfamily exhibit 
antimicrobial and immunomodulatory properties and hence contribute to the host 
defense [268, 269]. 
 
4.2.4 Implication of antibiotic-mediated suppression of AMPs on 
Clostridium difficile overgrowth in the gut 
Altered balance of normal gut flora after antibiotic treatment is regarded as the classical 
cause of CDAD development. Impaired immune responses have also been reported as 
important risk factors for CDAD [64]. To investigate if the suppression of AMPs in gut 
epithelia by antibiotics is associated with CDAD, antibacterial activity of LL-37 against 
C. difficile was evaluated in vitro. Incubation of two clinical isolates of ciprofloxacin-
resistant C. difficile with 5 µM LL-37 resulted in two log decrease of the colony 
forming units (CFU). In contrast two log increase of CFU was observed in media 
without LL-37. In a previous study, α- defensins including HD-5 were shown to inhibit 
the cytotoxic effect of C. difficile toxin B [270]. Therefore, reduction of the expression 
of LL-37, HBD-3 or additional AMPs after antibiotic treatment may allow overgrowth 
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of C. difficile in the gut and subsequent toxin-mediated damage. This hypothesis is 
supported by a previous finding, where downregulation of intestinal expression of 
RegIIIc, a secreted C-type lectin in antibiotic- treated mice was shown to increase the 
colonization of gut by vancomycin-resistant Enterococcus [271]. Furthermore, role of 
certain AMPs in regulating the composition of the gut flora has been reported [90]. 
Hence, Inhibition of the gut AMP expression can also contribute to the imbalance of 
microbial niche, promoting CDAD. 
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5 CONCLUSIONS 
 Downregulation of cathelicidin CAP-18 in the large intestinal epithelia of a 
rabbit model of shigellosis confirms our previous findings in patients with 
shigellosis (Figure 4). CAP-18 is also downregulated in the epithelia of lung 
and trachea of infected rabbits (paper I and III). 
 
 Oral treatment of Shigella-infected rabbits with NaB or PB counteracts the 
downregulation of CAP-18 in large intestinal epithelia and promotes secretion 
and processing of CAP-18 proform into active mature peptide in gut lumen. 
These activities correlate with reduced bacterial load and improved clinical and 
pathological outcome of shigellosis (Figure 4) (paper I and III). 
 
 Use of NaB enema as adjunct therapy to antibiotics in patients with shigellosis, 
leads to earlier reduction of inflammation and healing of mucosal damage of 
rectum along with enhanced expression and prolonged secretion of LL-37 in 
rectal epithelia and lumen, respectively (Figure 4) (paper II). 
 
 Restoration of downregulated CAP-18 in respiratory epithelia of Shigella-
infected rabbits by oral treatment with NaB or PB may lead to protection from 
secondary respiratory infections during shigellosis (paper III). 
 
 Suppression of AMPs and other innate immune components by antibiotics in 
colonic epithelia may contribute to CDAD, which has traditionally been known 
to occur via antibiotic-mediated imbalance of the intestinal flora (Figure 5) 
(paper IV). 
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Figure 4: Counteraction of Shigella-mediated downregulation of cathelicidins in 
large intestinal epithelia after treatment with NaB or PB, a schematic representation. 
(A) Abundant expression of LL-37/CAP-18 in large intestinal epithelia and also in the 
lumen of healthy host. (B) Downregulation of epithelial expression of LL-37/CAP-18 and 
influx of LL-37/CAP-18 producing inflammatory cells in the LP during Shigella infection. 
Detachment of dead epithelial cell from the epithelial lining indicates epithelial erosion. 
(C) After treatment with NaB or PB, LL-37/CAP-18 expression in the epithelia is restored 
and bacterial load is reduced, while inflammatory cells disappear from the LP. SE: surface 
epithelia; LP: lamina propria; NaB: sodium butyrate; PB: sodium-4-phenylbutyrate. 
A.    Healthy large intestinal mucosa 
B.    Shigella- infected large intestinal mucosa 
C.    Shigella- infected large intestinal 
mucosa after treatment with NaB/PB NaB/PB 
Mast cell Lymphocyte/
plasma cell 
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epithelial cell 
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Lumen 
LP 
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A.    Large intestinal mucosa and lumen in normal condition 
B.    Large intestinal mucosa and lumen after antibiotic treatment 
Figure 5: A schematic representation of colonization of large intestinal epithelia by 
Clostridium difficile after antibiotic-mediated disruption of the normal gut flora 
and suppression of AMPs. (A) Normal gut flora and AMPs create a preventive barrier 
against C. difficile. (B) Antibiotics disturb the balance of the normal flora as well as 
suppress the epithelial expression of AMPs, allowing overgrowth of C.difficile and 
subsequent colonization of the epithelia. AMP: antimicrobial peptide; SE: surface 
epithelia; LP: lamina propria. 
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6 FUTURE PERSPECTIVE 
Our findings indicate that the induction of AMPs at the site of infection by 
administration of extrinsic compounds can be a potential strategy of alternative or 
adjunct therapy to commonly used antibiotics. However, at present, induction studies 
have been limited to very few AMPs i.e. cathelicidins and defensins. Detailed 
understanding of the stimulation profile of additional antimicrobial peptides/proteins 
will put forward this therapeutic strategy. In addition, novel inducing components need 
to be explored that would upregulate numerous AMPs at infection sites. In order to 
continue the search for novel inducers, it is important to develop large scale screening 
methods. In this perspective, a colonic epithelial cell line, expressing luciferase under 
CAMP regulatory elements has recently been constructed in our laboratory. This stable 
cell line has responded successfully to known inducers and several novel inducers have 
been demonstrated for LL-37 expression (unpublished data). Cytotoxic and 
proinflammatory effects of excessive AMPs and the inducers per se should also be 
taken into account in order to make this strategy feasible. 
Regarding infections of the gut, the role of the mucus layer is a fascinating area of 
research. The mucus layer, overlying the epithelial surface of the gut, constitutes a 
physical barrier against pathogens and also against commensals, preventing direct 
contact with the epithelia. It also provides a chemical barrier by harboring effector 
molecules such as secretory IgA and several antimicrobial peptides/proteins, secreted 
from the underlying mucosa [272, 273]. It will be interesting to know, the expression 
profile of AMPs in the mucus layer in shigellosis, in enteric infections in general and 
after treatment with inducing components. The effect of antibiotics on mucosal 
expression of AMPs will also be intriguing. 
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